10-K: Twist Bioscience Reports Fiscal Year 2024 Results, Highlights Revenue Growth and Strategic Initiatives

Twist Bioscience's 10-K filing for fiscal year 2024 reveals a 28% increase in revenue, driven by strong performance in NGS tools and synthetic genes, alongside a focus on expanding manufacturing capacity and strategic partnerships.

Summary

• Twist Bioscience reported a 28% increase in revenue for fiscal year 2024, reaching $313 million, compared to $245.1 million in the previous year.
• The company's gross margin improved to 42.6% in fiscal year 2024, up from 36.6% in fiscal year 2023.
• Net losses for fiscal year 2024 were $208.7 million, slightly higher than the $204.6 million loss in fiscal year 2023.
• The company served approximately 3,562 customers in fiscal year 2024, with significant revenue contributions from the healthcare, chemicals/materials, and academic research sectors.
• Twist Bioscience shipped approximately 772,000 genes in fiscal year 2024, a 22% increase compared to the 634,000 genes shipped in fiscal year 2023.
• The company's net cash used in operating activities decreased to $64.1 million in fiscal year 2024, compared to $142.5 million in fiscal year 2023.
• The company has a strong intellectual property portfolio with over 150 issued or allowed patents and more than 250 pending patent applications as of September 30, 2024.
• The company is focused on expanding its manufacturing capacity, particularly at its Wilsonville, Oregon facility, to meet growing customer demand.
• Twist Bioscience is actively engaged in research and development to enhance existing products and develop new products, including mRNA and proteins.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong revenue growth and improved margins, but also acknowledges risks and challenges, resulting in a moderately positive sentiment.

Positives

• The company experienced significant revenue growth, indicating strong market demand for its products.
• The improvement in gross margin suggests increased efficiency and profitability.
• The increase in gene shipments demonstrates the company's ability to scale production and meet customer needs.
• The reduction in net cash used in operating activities indicates improved financial management.
• The company's diverse customer base and strong intellectual property portfolio position it well for future growth.
• The expansion into new product areas like RNA and proteins diversifies the company's revenue streams and market opportunities.
• The company's focus on digital data storage in DNA presents a significant long-term growth opportunity.

Negatives

• The company continues to incur net losses, although the loss for fiscal year 2024 was slightly higher than the previous year.
• The company is dependent on a single-source supplier for a critical component of its DNA synthesis process, which poses a supply chain risk.
• The company faces intense competition in the synthetic biology industry, which could impact its market share and pricing.
• The company's future success depends on its ability to manage growth effectively and expand into new markets.
• The company's products could be subject to additional regulation by the FDA or other regulatory agencies, which could increase costs and delay commercialization efforts.

Risks

• The company may require additional financing to achieve its goals, and a failure to obtain this capital could force delays or reductions in product development and manufacturing.
• Rapidly changing technology and extensive competition in synthetic biology could make the company's products obsolete or non-competitive.
• The company's continued success relies heavily on its disruptive technologies and products, particularly its silicon-based DNA synthesis platform.
• If the company is unable to expand its DNA synthesis manufacturing capacity, it could lose revenue and its business could be harmed.
• The company depends on one single-source supplier for a critical component for its DNA synthesis process, which could cause delays in the future capacity of its DNA synthesis process.
• The company depends on the continuing efforts of its senior management team and other key personnel, and the loss of such personnel could harm the company's ability to develop its products.
• The company may engage in strategic transactions, including acquisitions, that could disrupt its business, cause dilution to its stockholders, or reduce its financial resources.
• The company's products could be subject to additional regulation by the FDA or other regulatory agencies, which could increase costs and delay commercialization efforts.
• If the company fails to maintain proper and effective internal controls, its ability to produce accurate financial statements on a timely basis could be impaired.
• The company's ability to protect its intellectual property and proprietary technology through patents and other means is uncertain.

Future Outlook

The company intends to maintain and expand its position as a provider of high-quality synthetic DNA, become a leading supplier of NGS sample preparation products, conduct biopharma services, develop commercial solutions for storing digital data in DNA, and expand its global presence.

Management Comments

• We believe Twist Bioscience is uniquely positioned to help accelerate their efforts and the faster our customers succeed, the better for all of us.
• We have developed a disruptive DNA synthesis platform to industrialize the engineering of biology that provides DNA for a wide range of uses and markets.
• We believe our products enable a broad range of applications that may ultimately improve health and the sustainability of the planet across multiple industries.

Industry Context

The announcement highlights Twist Bioscience's position in the rapidly growing synthetic biology market, where synthetic DNA is a foundational product. The company's expansion into NGS tools and biopharma services reflects broader industry trends in personalized medicine and drug discovery. The company's exploration of DNA data storage positions it in an emerging market with significant potential.

Comparison to Industry Standards

• Twist Bioscience competes with a range of providers in the synthetic biology market, including GenScript Biotech Corporation, DNA Script, Inc., and Integrated DNA Technologies, Inc.
• In the NGS tools market, the company competes with Thermo Fisher Scientific Inc., Illumina, Inc., and Roche.
• In the antibody discovery market, the company competes with contract research organizations such as Curia, GenScript, and Genovac, and antibody discovery biotechnology companies such as Fair Journey/Iontas, Adimab, and AbCellera Biologics Inc.
• In the emerging field of DNA digital data storage, the company competes with Biomemory, Catalog Technologies, Inc., and various academic institutions.
• The company's silicon-based DNA synthesis platform differentiates it from competitors who use traditional plate-based methods, offering higher throughput and lower costs.
• The company's ability to provide rapid turnaround times for products at scale, such as its Express Genes offering, is a competitive advantage.

Legal Proceedings

• The company is involved in a securities class action lawsuit and a shareholder derivative suit, both related to allegations made in a report concerning the company's DNA chip technology and accounting practices.
• The company is subject to various legal proceedings and claims arising in the ordinary course of business.

Related Party Transactions

• The company purchased raw materials from related parties in the amount of $4.4 million, $6.8 million and $8.0 million for the years ended September 30, 2024, 2023 and 2022, respectively.
• The company recognized revenues from related parties in the amount of $12.1 million, $5.9 million and $3.5 million for the years ended September 30, 2024, 2023 and 2022, respectively.

Stakeholder Impact

• Shareholders may be impacted by the company's financial performance, strategic decisions, and any potential dilution from future capital raises.
• Employees may be impacted by changes in compensation, benefits, and job security.
• Customers may be impacted by the company's ability to deliver high-quality products and services in a timely manner.
• Suppliers may be impacted by the company's ability to maintain stable supply chains and meet its financial obligations.
• Creditors may be impacted by the company's ability to repay its debts and maintain a healthy financial position.

Next Steps

• The company intends to maintain and expand its position as a provider of high-quality synthetic DNA.
• The company aims to become a leading supplier of NGS sample preparation products.
• The company plans to conduct biopharma services for current and future partners.
• The company will continue to develop commercial solutions for storing digital data in DNA.
• The company intends to expand its global presence.

Key Dates

Keywords

synthetic biology, DNA synthesis, next-generation sequencing, NGS, antibody discovery, biopharma, data storage, oligonucleotides, gene synthesis, genomics